增材制造SmartEx QD 100设计的口服含有伊索尼亚齐德的三维打印板,通过选择性激光烧结即时释放到胃中
Tukaram Karanwad1, Sachin B Jorvekar2, Santa Mandal3
1Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, Changsari, Assam 781101, India.
Molecular pharmaceutics
|August 27, 2024
概括
SmartEx QD 100 (SM QD 100) 是一种用于选择性激光烧结 (SLS) 介导的3D打印的新型辅助剂. 它成功地制造了含有异化 (INH) 的稳定,立即释放的药片,具有有利的药理动力学.
科学领域:
- 制药技术 制药技术 制药技术
- 材料科学 材料科学 材料科学
- 药物输送系统 药物输送系统
背景情况:
- 材料选择和药物兼容性是制药3D打印中的关键挑战.
- 选择性激光烧结 (SLS) 是一种有前途的3D打印技术,用于制造定制剂型.
- 需要新的助剂来克服目前用于药物输送的3D打印材料的局限性.
研究的目的:
- 引入和评估SmartEx QD 100 (SM QD 100) 作为一种用于SLS介导3D打印的新型辅助剂.
- 通过SLS.通过SM QD 100评估制造含有异化 (INH) 的即时胃释放片的可行性.
- 描述3D打印平板电脑的物理化学特性,并评估3D打印平板电脑的体外和体内性能.
主要方法:
- 使用SLS与SM QD 100和INH的物理混合物制造3D打印平板电脑.
- 使用各种分析技术制造的3D打印件的物理化学表征.
- 在体外释放药物的研究,以确认胃即时释放.
- 在口服后使用经过验证的LC-APCI-MS/MS方法对子进行体内药理学分析.
- 3D打印平板电脑的加速稳定性测试.
主要成果:
- 通过SLS,SM QD 100使INH嵌入式3D打印平板电脑的成功制造成为可能.
- 优化的3D打印机在15分钟内显示出100%的INH释放,证实了立即的胃释放.
- 3D打印的平板电脑在加速条件下表现出良好的稳定性,持续了三个月.
- 药理动力学研究证实了INH从3D打印剂型中吸收的速度和程度.
结论:
- SmartEx QD 100 (SM QD 100) 是一种可行的新型辅助剂,用于稳定,立即释放的药物配方的SLS介导的3D打印.
- 开发的3D打印平板显示了有效的药物输送应用的潜力.
- SM QD 100促进了先进的3D打印药物产品的创建,具有理想的释放配置和稳定性.
相关概念视频
01:27Drug Delivery Systems: Different Types
420
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
420
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
175
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
175
01:26Oral Drug Delivery Systems: Continuous-Release Systems
323
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
323
01:11Oral Drug Delivery Systems: Delayed-Release Systems
229
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
229